December 17, 2020 -- The government of New Zealand has agreed to purchase 10.7 million doses of Novavax's COVID-19 vaccine candidate, NVX-CoV2373.
The vaccine candidate is currently being evaluated in a phase III clinical trial in the U.K. NVX-CoV2373 is a recombinant spike protein vaccine adjuvanted with Novavax's proprietary Matrix-M to enhance immune response.
Under the agreement, Novavax will manufacture NVX-CoV2373 with a target of delivering initial doses by mid-2021. The company will work with Medsafe, New Zealand's regulatory agency to obtain the necessary product approvals. Additional financial terms of the agreement were not disclosed.